<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410603</url>
  </required_header>
  <id_info>
    <org_study_id>15-000373</org_study_id>
    <nct_id>NCT02410603</nct_id>
  </id_info>
  <brief_title>Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer</brief_title>
  <official_title>Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the detection of circulating tumor DNA, soluble&#xD;
      immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our plan is to collect blood from patients with advanced stage lung cancer who are scheduled&#xD;
      to undergo systemic therapy. In this study we will utilize a novel technology for circulating&#xD;
      tumor DNA detection in order to evaluate their presence in patients with lung cancer by&#xD;
      comparing blood samples at six time points. We will obtain baseline blood and then collect&#xD;
      blood at five time points during the course of the patient's chemotherapy treatments and at&#xD;
      the end of treatment. These same blood collections will be used for the detection of soluble&#xD;
      immune markers and evaluation of PBMCs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point is the number and type of mutations detectable in the circulating tumor DNA blood samples.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">64</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Neoplasms</condition>
  <condition>Cancer of Lung</condition>
  <condition>Cancer of the Lung</condition>
  <condition>Neoplasms, Lung</condition>
  <condition>Neoplasms, Pulmonary</condition>
  <condition>Pulmonary Cancer</condition>
  <condition>Pulmonary Neoplasms</condition>
  <condition>Carcinoma, Non-small-cell Lung</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced stage cancer in the thorax who are scheduled to undergo systemic&#xD;
        therapy at the Mayo Clinic in Rochester, MN.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced (non-resectable) malignancy in the thorax&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
          -  No prior history of neoadjuvant therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old&#xD;
&#xD;
          -  Unable to provide consent&#xD;
&#xD;
          -  Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential&#xD;
             iatrogenic anemia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Mansfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Aaron S. Mansfield, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

